Related Experiment Video
Updated: Jun 16, 2025
08:55
Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
Published on: November 20, 2017
9.7K
Short-term therapy with R568 ameliorated secondary hyperparathyroidism but does not prevent aortic valve
Asmahan Abu-Snieneh1, Irina Gurt2, Suzan Abedat1
1Heart Institute, Cardiovascular Research Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Frontiers in Nephrology
|August 21, 2024
Summary
Calcimimetic R568 reduced parathyroid hormone (PTH) in uremic rats but did not impact aortic valve calcification (AVC). Effective AVC treatment requires lowering both PTH and phosphate levels, suggesting combination therapy for chronic kidney disease (CKD).
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Renal failure-associated aortic valve calcification (AVC) stems from hyperphosphatemia and hyperparathyroidism.
- Calcimimetics are used to manage secondary hyperparathyroidism.
Purpose of the Study:
- To assess the impact of the calcimimetic R568 on aortic valve calcification (AVC) in a rat model of chronic kidney disease (CKD).
Main Methods:
- Rats were administered a uremic, phosphate-rich diet for six weeks, with daily R568 injections.
- Biochemical markers (urea, creatinine, PTH, calcium, phosphate), AVC progression (von Kossa staining), inflammation (CD68), and osteoblastic markers (Runx2, Osteopontin, Osteocalcin) were analyzed.
Main Results:
- R568 significantly reduced parathyroid hormone (PTH) levels but did not alter serum calcium or phosphate.
- Aortic valve calcification (AVC) and inflammatory markers (CD68) increased in uremic rats and were unaffected by R568.
- Osteoblastic markers (Runx2, Osteopontin, Osteocalcin) were upregulated in uremic rats but not influenced by R568 treatment.
Conclusions:
- Short-term R568 therapy in an adenine-induced uremic rat model did not affect AVC progression.
- R568 effectively lowered PTH but failed to reduce elevated phosphate levels, indicating that addressing both is crucial for AVC regression.
- Combination therapy with R568 and phosphate binders may be necessary for managing CKD-associated AVC, warranting further investigation.
